José Valentín
García Gutiérrez
Profesor/a Asociado/a en CC. de la Salud
Hospital Universitario de Salamanca
Salamanca, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Universitario de Salamanca (23)
2024
-
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study
Annals of Hematology, Vol. 103, Núm. 10, pp. 4045-4055
-
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
Leukemia
-
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
HemaSphere
-
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
Frontiers in Oncology, Vol. 14
-
Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib
Annals of Hematology, Vol. 103, Núm. 11, pp. 4537-4544
-
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis
American Journal of Hematology
2023
-
Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients
Viruses, Vol. 15, Núm. 10
-
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
Bone Marrow Transplantation, Vol. 58, Núm. 5, pp. 567-580
-
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
Cancers, Vol. 15, Núm. 4
2022
-
Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH
Clinical and Translational Oncology, Vol. 24, Núm. 5, pp. 770-783
-
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group
American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42
-
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550
-
Tyrosine kinase inhibitor dose reduction during the management ofaccelerated phase chronic myeloid leukemia
Leukemia Research
2021
2020
-
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
Leukemia, Vol. 34, Núm. 8, pp. 2125-2137
-
Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes
Journal of Molecular Diagnostics, Vol. 22, Núm. 10, pp. 1217-1224
-
Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model
Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 12, pp. 2237-2244
-
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk
Leukemia, Vol. 34, Núm. 10, pp. 2648-2659
2019
2018
-
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Annals of Hematology, Vol. 97, Núm. 11, pp. 2089-2098